{"entity":{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","aka":["Hangzhou Sumgen Biotech Co., Ltd."],"tldr":"Hangzhou Sumgen Biotech is a China-based biotechnology company running 2 late-stage cancer trials of SG2918 and SG301 in multiple myeloma.","summary":"Hangzhou Sumgen Biotech, based in Hangzhou, China, is a biotechnology company. Sumgen Biotech is a biotech company focused on innovative drug development in oncology, specialising in antibody drugs including monoclonal antibodies and antibody-drug conjugates. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing SG2918 and SG301 in multiple myeloma. The largest, NCT06508983 (A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients), plans to enrol 360 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sumgenbio.com"},{"label":"ClinicalTrials.gov: trials led by Hangzhou Sumgen Biotech","url":"https://clinicaltrials.gov/search?lead=Hangzhou%20Sumgen%20Biotech%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["sg301"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07454187"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hangzhou","country":"CN","companyType":"biotech","website":"https://www.sumgenbio.com","founded":2015,"stage":"growth","investors":[],"funding":[]},"route":"/companies/hangzhou-sumgen-biotech/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/"}],"trial":[{"id":"nct06508983","kind":"trial","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","route":"/trials/nct06508983/"},{"id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07454187/"}]}}